Tempest Therapeutics adds financial veteran John W. Frederick to its board, bolstering the company's leadership team as it advances its clinical-stage CAR-T pipeline.
Appointment of John W. Frederick to the board adds financial and capital markets expertise, but no immediate operational or financial impact is disclosed.
Tempest Therapeutics, a clinical-stage biotechnology firm, has appointed John W. Frederick to its board of directors. Frederick brings extensive expertise in financial strategy, capital markets, and corporate governance to the company as it continues to develop its in vivo CAR-T therapies for cancer and autoimmune diseases.
John W. Frederick is an executive with extensive experience in financial strategy, capital markets, corporate governance, and operational transformation.
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T therapies to treat cancer and autoimmune diseases.